Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06683014 · ClinicalTrials.gov registry record · Phase 2
MDMA in Borderline Personality Disorder
A Phase 2 study of Borderline Personality Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06683014: Recruiting Phase 2 study of Borderline Personality Disorder, sponsored by Yale University.
NCT06683014 is a Phase 2 study of Borderline Personality Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 10 participants, below the 107-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06683014, a Phase 2 study of Borderline Personality Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.
Primary Outcome
Defined as sociability visual-analogue scale (VAS) score. Total score range is 0-100, higher scores indicating more sociability.
Conditions Studied
Interventions
- DRUG MDMA
Study Locations (1)
Connecticut
- Connecticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-09-05 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT06683014 shows while recruiting
NCT06683014 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 107-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Borderline Personality Disorder appearing as the primary indexed condition, and to 1 intervention - of which MDMA is the first listed.
NCT06683014 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06683014 about?
NCT06683014 is a clinical study titled "MDMA in Borderline Personality Disorder". The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.
What is the current status of trial NCT06683014?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-09-05. Estimated completion is 2026-09.
What conditions does trial NCT06683014 study?
This clinical trial studies the following conditions: Borderline Personality Disorder.
What interventions are being tested in trial NCT06683014?
The interventions under investigation include: MDMA (DRUG).
Who is sponsoring clinical trial NCT06683014?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06683014 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Borderline Personality Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06683014's enrollment target sits among peer trials
10 16th of 16 higher than 1 of 16 other Borderline Personality Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Borderline Personality Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder
RECRUITING · Phase 2
-
Treatment of Suicidal Women With Borderline Personality Disorder
COMPLETED · Phase 2
-
Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
COMPLETED · Phase 2
-
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
RECRUITING · NA
-
Cognitive Reappraisal Training for Borderline Personality (BPD)
RECRUITING · NA
-
Treatment of Borderline Personality Disorder With rTMS
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI